Influence of Lenvatinib on the Functional Reprogramming of Peripheral Myeloid Cells in the Context of Non-Medullary Thyroid Carcinoma

Lenvatinib is a multitarget tyrosine kinase inhibitor (TKI) approved for the treatment of several types of cancers, including metastatic differentiated thyroid cancer (DTC). The intended targets include VEGFR 1–3, FGFR 1–4, PDGFRα, RET, and KIT signaling pathways, but drug resistance inevitably deve...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Chunying, Rabold, Katrin, Netea, Mihai G., Jaeger, Martin, Netea-Maier, Romana T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9960916/
https://www.ncbi.nlm.nih.gov/pubmed/36839733
http://dx.doi.org/10.3390/pharmaceutics15020412

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9960916/
https://www.ncbi.nlm.nih.gov/pubmed/36839733
http://dx.doi.org/10.3390/pharmaceutics15020412

Ejemplares similares